One of cardiology's oldest drug classes is getting a rigorous second look — and the evidence may shift how clinicians approach patients whose heart failure remains poorly controlled despite modern therapies. For the substantial population living with reduced or mildly reduced ejection fraction heart failure, additional therapeutic options carry real quality-of-life and survival implications.
This JAMA meta-analysis pooled data from three large placebo-controlled randomized trials encompassing 9,013 patients with heart failure with reduced ejection fraction (HFrEF) or mildly reduced ejection fraction (HFmrEF), with a weighted mean age of 64.5 years and 22% female representation. Using a fixed-effects model, investigators assessed the composite primary endpoint of cardiovascular death or first worsening heart failure event, alongside all-cause mortality as a secondary outcome. The composite event occurred in 41% of the digitalis glycoside group, with hazard ratios and confidence intervals providing the quantitative signal — details the original article elaborates on — suggesting a meaningful reduction in the composite endpoint compared with placebo.
Digitalis compounds, derived from the foxglove plant and used medicinally for over two centuries, work primarily by inhibiting the sodium-potassium ATPase pump, increasing myocardial contractility and modulating autonomic tone. Their clinical reputation has been complicated: the landmark DIG trial (1997) showed digoxin reduced hospitalizations without improving mortality, and concerns about narrow therapeutic windows and arrhythmia risk dampened enthusiasm. Contemporary heart failure management now centers on neurohormonal blockade — ACE inhibitors, beta-blockers, mineralocorticoid antagonists, and SGLT2 inhibitors — leaving digitalis as a niche add-on.
This meta-analysis is incremental rather than paradigm-shifting, but it is clinically meaningful because it specifically addresses HFmrEF, a phenotype that has historically been underrepresented in trials. The analysis is limited by the small number of eligible studies (three), the male predominance (78%), and the inability to fully account for background guideline-directed therapy that has evolved substantially since the original trials. Nonetheless, publication in JAMA signals the finding warrants serious reconsideration in contemporary treatment algorithms.